Pregnancy: REKOVELLE is not indicated during pregnancy. No teratogenic risk has been reported, following controlled ovarian stimulation, in clinical use with gonadotropins. There are no data from the inadvertent exposure to REKOVELLE in pregnant women. Studies in animals have shown reproductive toxicity with REKOVELLE doses above the recommended maximal dose in humans (see Pharmacology: Toxicology: Preclinical Safety Data under Actions).
Breast-feeding: REKOVELLE is not indicated during breastfeeding.
Fertility: REKOVELLE is indicated for use in infertility (see Indications/Uses).